HA-1 T TCR T Cell Immunotherapy for Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Phase 1
24
about 10 years
≤80
1 site in WA
What this study is about
This trial is testing a new treatment called HA-1 T cell immunotherapy in adults who have relapsed or refractory acute leukemia after a donor stem cell transplant. The treatment involves collecting and modifying donor cells to recognize HA-1 markers on leukemia cells, which are then infused back into the patient.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
- 2.Undergo Biospecimen Collection
- 3.Undergo Bone Marrow Aspiration
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Proportion of subjects who develop new or recurrent symptoms or signs of graft-versus-host disease
diagnostic, biopsy
Oncology